Thrombosis prophylaxis in patients with ischaemic (cardioembolic) stroke. How long is long enough?

Keyphrases

• Absence of Evidence 33%
• Antithrombotic Drugs 33%
• Antithrombotic Therapy 33%
• Atrial Fibrillation 66%
• Bleeding Risk 33%
• Cardiac Disease 66%
• Cardioembolic Stroke 100%
• Cardioembolism 100%
• Clinical High Risk 33%
• Drug Regime 33%
• High Mortality 33%
• Imaging Modalities 33%
• Ischemic Stroke 66%
• Long-term Complications 33%
• Most Common Cause 33%
• Non-homogeneity 33%
• Non-valvular Atrial Fibrillation 33%
• Overall Risk 33%
• Risk Factors 33%
• Risk Profile 33%
• Stroke Risk 33%
• Technological Improvement 33%
• Thromboprophylaxis 100%
• Vitamin K Antagonists 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 33%
• Antithrombotic Therapy 33%
• Antivitamin K 33%
• Atrial Fibrillation 100%
• Brain Ischemia 66%
• Cardioembolic Stroke 100%
• Cerebrovascular Accident 33%
• Recurrent Disease 33%
• Thrombosis 100%

Medicine and Dentistry

• Antithrombotic 33%
• Antithrombotic Therapy 33%
• Apoplexy 33%
• Atrial Fibrillation 100%
• Brain Ischemia 66%
• Cardioembolic Stroke 100%
• Recurrent Disease 33%
• Thrombosis Prevention 100%
• Vitamin K Antagonist 33%